Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Assets (2016 - 2025)

Ironwood Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $122.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 27.18% year-over-year to $122.7 million; the TTM value through Dec 2025 reached $562.8 million, down 31.99%, while the annual FY2025 figure was $122.7 million, 27.18% down from the prior year.
  • Non-Current Assets for Q4 2025 was $122.7 million at Ironwood Pharmaceuticals, roughly flat from $122.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $387.0 million in Q2 2021 and bottomed at $61.1 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $254.1 million (2023), against an average of $254.0 million.
  • The largest annual shift saw Non-Current Assets surged 550.77% in 2021 before it plummeted 42.05% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $381.7 million in 2021, then fell by 16.19% to $319.9 million in 2022, then decreased by 25.67% to $237.8 million in 2023, then decreased by 29.12% to $168.5 million in 2024, then decreased by 27.18% to $122.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Non-Current Assets are $122.7 million (Q4 2025), $122.2 million (Q3 2025), and $151.2 million (Q2 2025).